Document is current

Article History

Received: 23 May 2025

Accepted: 2 August 2025

First Online: 14 August 2025

Declarations

:

: All data used in the study consisted of aggregated and anonymised secondary data, acquired with the approval of the data owner. As a result, approval from an Institutional Review Board or independent ethics committee was not required. Since the data were aggregated and anonymised and contained no personal patient information, informed consent was not necessary. The study complied with legal and regulatory standards, adhering to the International Epidemiological Association’s Good Epidemiological Practice guidelines to ensure scientific value and rigour.

: Not applicable.

: Maribel Casas, Robin Bruyndonckx, Mikel Esnaola, Somsuvro Basu, Worku Biyadgie Ewnetu, Pimnara Peerawaranun, Solomon Molalign, and Aleksandra Polkowska-Kramek are employees of P95 Clinical and Epidemiology Services, which received funding from Pfizer in connection with the development of this manuscript and research. Tor Molden, Caihua Liang, Bradford D. Gessner, and Elizabeth Begier are Pfizer employees and may own Pfizer stock.

: Information from the Norwegian Patient Registry (NPR) and the Norwegian Cause of Death Registry (CoDR) has been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the NPR and CoDR is intended nor should be inferred.